Skip to main content
MedPathMedPath Home
Clinical Trials/JPRN-jRCTs031220683
JPRN-jRCTs031220683
Recruiting
Phase 2

Investigation of efficacy and safety of Sequence treatment of Cabazitaxel administation after 3 courses of Docetaxel for castration-resistant prostate cancer

Taguchi Satoru0 sites20 target enrollmentMarch 3, 2023
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionscastration-resistant prostate cancerCRPC

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
castration-resistant prostate cancer
Sponsor
Taguchi Satoru
Enrollment
20
Status
Recruiting
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 3, 2023
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
Male

Investigators

Sponsor
Taguchi Satoru

Eligibility Criteria

Inclusion Criteria

  • •(1\) Diagnosed with metastatic castrate\-resistant prostate cancer
  • •(2\) Scheduled to take docetaxel
  • •(3\) Male, aged 18 years and above at the time of informed consent
  • •(4\) Able and willing to give written informed consent with sufficient understanding after having received sufficient explanation
  • •(5\) Able to attend all scheduled visits

Exclusion Criteria

  • •(1\) With chemotherapy intolerance
  • •(2\) With a history of taking docetaxel or cabazitaxel
  • •(3\) With severe liver failure, renal failure, or cardiac disease (judged by CTCAE v5\.0\-JCOG grade 3\)
  • •(4\) With severe myelosuppression (judged by CTCAE v5\.0\-JCOG grade 3\)
  • •(5\) With systemic infection
  • •(6\) Suspected of infectious disease with fever
  • •(7\) Suspected of intestinal pneumonia
  • •(8\) With a history of severe allergy to docetaxel, cabazitaxel, or drugs containing polysorbate 80
  • •(9\) With malignancy other than prostate cancer
  • •(10\) With a history of severe drug allergy including anaphylactic shock, or a history of severe side effects

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 4
comparison of effectiveness and safety of topical sequential therapy with tazarotene and calcitriol with monotherapy of calcitriol or tazarotene in patients with stable plaque psoriasis.Health Condition 1: L408- Other psoriasisHealth Condition 2: null- stable plaque psoriasis
CTRI/2020/03/023715nil120
Not yet recruiting
Phase 1
Investigating targEting LysyL oxIdase tO ameliorate scarring in burn Traumaburn injurySkin - Other skin conditionsInjuries and Accidents - Burns
ACTRN12623001071617university of western australia60
Completed
Not Applicable
The evaluation of the efficacy and the safety of TSUMURA Tokishakuyakusan Extract Granules for Ethical Use on endometriosis patients with dysmenorrheaEndometriosis
JPRN-UMIN000017908Tottori University Faculty of Medicine15
Recruiting
Phase 1
Investigation of fractional CO2 laser and adipose tissue exosome in the treatment of acne scars and skin rejuvenatioCondition 1: Skin aging. Condition 2: Atrophic scar.Atrophic disorder of skinScar conditions and fibrosis of skinL90.9L90.5
IRCT20200127046282N52Tehran University of Medical Sciences16
Recruiting
Phase 3
Study of Out of Specification for TisagenlecleucelPediatric/young adult patients with r/r pALL and adult patients with r/r LBCL (including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma) for Part 1, and r/r ALL and r/r NHL for Part 2.
JPRN-jRCT1080224903ovartis Pharma. K.K.200